CPC C12N 5/0645 (2013.01) [A61K 35/15 (2013.01); A61P 35/00 (2018.01); C07K 14/4703 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70535 (2013.01); C07K 14/70596 (2013.01); C07K 16/2896 (2013.01); C07K 16/32 (2013.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C12N 2501/24 (2013.01); C12N 2501/52 (2013.01); C12N 2510/00 (2013.01); C12N 2740/15043 (2013.01)] | 10 Claims |
1. A method of modifying ex vivo a macrophage or monocyte comprising a chimeric antigen receptor (CAR) comprising:
(a) an extracellular domain,
(b) a transmembrane domain, and
(c) an intracellular domain, and
wherein the method comprises treating the macrophage or monocyte with a CD40 agonist,
thereby producing a modified macrophage or monocyte which exhibits increased tumor killing ability relative to an unmodified macrophage or monocyte.
|